CA2211324A1 - Alpha-foetoproteine humaine recombinante et ses utilisations - Google Patents
Alpha-foetoproteine humaine recombinante et ses utilisationsInfo
- Publication number
- CA2211324A1 CA2211324A1 CA002211324A CA2211324A CA2211324A1 CA 2211324 A1 CA2211324 A1 CA 2211324A1 CA 002211324 A CA002211324 A CA 002211324A CA 2211324 A CA2211324 A CA 2211324A CA 2211324 A1 CA2211324 A1 CA 2211324A1
- Authority
- CA
- Canada
- Prior art keywords
- fetoprotein
- human alpha
- cell
- recombinant human
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Marine Sciences & Fisheries (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
Abstract
De façon générale, on divulgue des méthodes pour inhiber la prolifération des cellules immunitaires autoréactives chez un mammifère, comportant l'administration au mammifère d'une quantité thérapeutiquement efficace d'une alpha-foetoprotéine humaine recombinante ou d'un fragment anti-prolifération des cellules immunitaires ou d'un analogue de cette dernière; des méthodes pour inhiber un néoplasme chez un mammifère, comportant l'administration au mammifère d'une quantité thérapeutiquement efficace d'une alpha-foetoprotéine humaine recombinante ou d'un fragment anti-néoplasme ou d'un analogue de cette dernière; ainsi que des méthodes de culture cellulaire, comportant l'utilisation d'un milieu contenant de l'alpha-foetoprotéine humaine ou un fragment ou un analogue de cette dernière.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37731695A | 1995-01-24 | 1995-01-24 | |
US37731195A | 1995-01-24 | 1995-01-24 | |
US37731795A | 1995-01-24 | 1995-01-24 | |
US08/377,309 | 1995-01-24 | ||
US08/377,311 | 1995-01-24 | ||
US08/377,317 | 1995-01-24 | ||
US08/377,309 US5965528A (en) | 1991-09-27 | 1995-01-24 | Recombinant human alph-fetoprotein as an immunosuppressive agent |
US08/377,316 | 1995-01-24 | ||
US08/505,012 | 1995-07-21 | ||
US08/505,012 US6331611B1 (en) | 1991-09-27 | 1995-07-21 | Expression and purification of cloned human alpha-fetoprotein |
PCT/US1996/000996 WO1996022787A1 (fr) | 1995-01-24 | 1996-01-24 | Alpha-f×toproteine humaine recombinante et ses utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2211324A1 true CA2211324A1 (fr) | 1996-08-01 |
CA2211324C CA2211324C (fr) | 2012-07-10 |
Family
ID=27541364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2211324A Expired - Lifetime CA2211324C (fr) | 1995-01-24 | 1996-01-24 | Alpha-foetoproteine humaine recombinante et ses utilisations |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0805687A4 (fr) |
JP (2) | JPH10513347A (fr) |
CN (1) | CN1150030C (fr) |
AU (1) | AU700975B2 (fr) |
CA (1) | CA2211324C (fr) |
HK (1) | HK1010153A1 (fr) |
WO (1) | WO1996022787A1 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965528A (en) | 1991-09-27 | 1999-10-12 | Mcgill University | Recombinant human alph-fetoprotein as an immunosuppressive agent |
US6288034B1 (en) | 1995-01-24 | 2001-09-11 | Martinex R & D Inc. | Recombinant human alpha-fetoprotein as an immunosuppressive agent |
WO1998035981A1 (fr) * | 1997-02-13 | 1998-08-20 | The Regents Of The University Of California | Prevention et traitement du cancer hepatocellulaire |
WO2001058922A2 (fr) * | 2000-02-10 | 2001-08-16 | The Regents Of The University Of California | Methodes et compositions destinees au traitement du cancer hepatocellulaire |
US7098306B2 (en) | 1997-02-13 | 2006-08-29 | The Regents Of The University Of California | Method and compositions for treating hepatocellular cancer |
EP1958503A3 (fr) * | 1999-01-06 | 2008-11-26 | Merrimack Pharmaceuticals, Inc. | Expression d'alpha féto-protéines humaines secrétées dans des animaux transgéniques |
US7208576B2 (en) | 1999-01-06 | 2007-04-24 | Merrimack Pharmaceuticals, Inc. | Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof |
WO2001003501A2 (fr) * | 1999-07-12 | 2001-01-18 | Universite Libre De Bruxelles | Mammifere non humain genetiquement modifie presentant une carence d'alpha-foetoproteine |
US7022892B1 (en) | 1999-07-12 | 2006-04-04 | Universite Libre De Bruxelles | Non-human genetically modified mammal lacking the alpha-fetoprotein |
FI118263B (fi) * | 2002-10-09 | 2007-09-14 | Timo Kalevi Korpela | Kaspaasiaktiivisuutta säätelevät peptidit |
US7074561B2 (en) * | 2002-10-22 | 2006-07-11 | Biomerieux, Inc. | Isothermal amplification based assay for the detection and quantitation of alpha-fetoprotein mRNA |
EP1789066A4 (fr) * | 2004-09-09 | 2009-10-28 | Serometrix Llc | Compositions et methodes d'utilisation de peptides inhibiteurs de la croissance de l'alpha-fetoproteine |
US8932829B2 (en) | 2005-07-07 | 2015-01-13 | Elena Dudich | Recombinant alpha-fetoprotein and compositions thereof |
GB0617564D0 (en) * | 2006-09-06 | 2006-10-18 | Ucl Business Plc | Peptides and methods |
CN101743018A (zh) * | 2006-12-19 | 2010-06-16 | 梅里麦克药品公司 | 甲胎蛋白和免疫调谐剂的共同施用以治疗多发性硬化 |
WO2008113970A2 (fr) * | 2007-03-16 | 2008-09-25 | Ucl Business Plc | Peptides |
CN105732795A (zh) * | 2016-03-21 | 2016-07-06 | 海南医学院 | 一种获得人类甲胎蛋白的方法 |
CN112898399A (zh) * | 2019-12-03 | 2021-06-04 | 香雪生命科学技术(广东)有限公司 | 源自于afp抗原的短肽 |
CN113416729B (zh) * | 2021-05-18 | 2022-11-22 | 遵义医科大学附属医院 | 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5486602A (en) * | 1977-10-27 | 1979-07-10 | Hoffmann La Roche | Production of purified alpha 1 phetoprotein |
JPH025866A (ja) * | 1988-06-27 | 1990-01-10 | Kansai Shin Gijutsu Kenkyusho:Kk | ヒトアルファフェトプロテインドメインi遺伝子、対応プラスミド組換体、対応形質転換体、該ドメインiの製造法及び製造された該ドメインi |
IT1226551B (it) * | 1988-07-29 | 1991-01-24 | Sclavo Spa | Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico |
EP0356399A3 (fr) * | 1988-08-26 | 1991-03-20 | Sandoz Ag | Dérivés substitués du 4-azatricyclo (22.3.1.04.9) octacos-18-ène, leur préparation et les compositions pharmaceutiques les contenant |
US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
US5206153A (en) * | 1990-06-27 | 1993-04-27 | Snow Brand Milk Products Co., Ltd. | Method of producing human α-fetoprotein and product produced thereby |
WO1993005774A1 (fr) * | 1991-09-25 | 1993-04-01 | Wisconsin Alumni Research Foundation | Complexes d'antibiotiques d'anthracycline et d'acides gras polyinsatures dans des emulsions de lipides |
CA2120131A1 (fr) * | 1991-09-27 | 1994-05-11 | Robert A. Murgita | Expression et purification d'alphafoetoproteine humaine clonee |
DE59509887D1 (de) * | 1994-09-26 | 2002-01-10 | Infineon Technologies Ag | Koppelanordnung zum optischen aneinanderkoppeln eines oeic-bausteins und optischer fasern |
-
1996
- 1996-01-24 AU AU49035/96A patent/AU700975B2/en not_active Expired
- 1996-01-24 CN CNB96192764XA patent/CN1150030C/zh not_active Expired - Lifetime
- 1996-01-24 EP EP96905219A patent/EP0805687A4/fr not_active Ceased
- 1996-01-24 CA CA2211324A patent/CA2211324C/fr not_active Expired - Lifetime
- 1996-01-24 WO PCT/US1996/000996 patent/WO1996022787A1/fr not_active Application Discontinuation
- 1996-01-24 JP JP8523001A patent/JPH10513347A/ja active Pending
-
1998
- 1998-10-15 HK HK98111257A patent/HK1010153A1/xx not_active IP Right Cessation
-
2007
- 2007-09-19 JP JP2007243055A patent/JP2008073041A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0805687A1 (fr) | 1997-11-12 |
CA2211324C (fr) | 2012-07-10 |
JPH10513347A (ja) | 1998-12-22 |
AU4903596A (en) | 1996-08-14 |
HK1010153A1 (en) | 1999-06-17 |
AU700975B2 (en) | 1999-01-14 |
JP2008073041A (ja) | 2008-04-03 |
WO1996022787A1 (fr) | 1996-08-01 |
CN1179106A (zh) | 1998-04-15 |
EP0805687A4 (fr) | 2000-05-31 |
CN1150030C (zh) | 2004-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2211324A1 (fr) | Alpha-foetoproteine humaine recombinante et ses utilisations | |
Casey et al. | Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography | |
AU725238B2 (en) | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers | |
FI103181B (fi) | Uusi vasta-aine ja siihen liittyvät vasta-ainekonjugaatit, DNA-sekvens sit, ilmentämisvehikkelit ja solut | |
CA2287872A1 (fr) | Compositions immunogenes dirigees contre le recepteur de cck-b/gastrine et procede de traitement des tumeurs | |
EP0334165A2 (fr) | Anticorps monoclonaux | |
JPH05184384A (ja) | hBNPのC端を認識するモノクロ−ナル抗体 | |
KR20200143366A (ko) | 수식 항체 및 방사성 금속 표지 항체 | |
US6355444B1 (en) | Carcinoma associated antigen (SK1) monoclonal antibodies against SK1, methods of producing these antibodies and uses therefor | |
CA2343979A1 (fr) | Interleukine humaine b50, ses utilisations therapeutiques | |
US6403096B1 (en) | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof | |
CA2240409A1 (fr) | Genes de chemokine cx3c mammalienne | |
AU722904B2 (en) | Novel polynucleotides PANC1A and PANC1B associated with pancreatic cancer | |
WO1998008866B1 (fr) | Bau, une proteine interactive associee a la sequence bin1, et utilisations | |
US5496705A (en) | Monoclonal antibody specific for rat synaptophysin | |
AU596670B2 (en) | Assays and antibodies for n-myc proteins | |
Lam | Treatment of B-cell lymphoma using peptides. A novel concept. | |
Greiner et al. | Modulation of human tumor antigen expression | |
CN109593131B (zh) | 一种抗14-3-3η蛋白单克隆抗体及其用途 | |
Rathjen et al. | Selective enhancement of tumour necrosis factor activity: mapping regions with monoclonal antibodies | |
EP0931836B1 (fr) | Peptide dérivé de l'interleukine-2 humaine pouvant accroître la perméablilté vasculaire et les immunoconjugués en dérivant | |
JPH11508235A (ja) | 腫瘍関連エピトープ | |
US20040156824A1 (en) | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof | |
JPH03163095A (ja) | ヒト神経成長因子の部分ペプチド、抗体およびその用途 | |
Ozker | Current developments in single photon radiopharmaceuticals for tumor imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20160125 |